Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe tumor environment to predict drug resistance in stomach cancer

NCT ID NCT07692477

Not yet recruiting Knowledge-focused Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study investigates why some stomach cancers do not respond to a standard chemotherapy combination (FLOT) plus the immunotherapy drug durvalumab. Researchers will analyze tumor samples and blood from 250 patients with operable stomach or gastroesophageal junction cancer. By mapping immune and blood vessel-related features in the tumor environment, they aim to identify markers that predict treatment response or resistance. The goal is to improve personalized treatment decisions for future patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could lead to better ways to predict which patients will benefit from chemotherapy plus immunotherapy, potentially improving treatment choices.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. The findings may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC ADENOCARCINOMA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (SIEWERT II-III)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.